BioCardia targets Japan PMDA submission for CardiAMP by end of 2026
BioCardia has outlined a set of near-term regulatory and commercial priorities to shareholders, with a Japan approval submission for its CardiAMP autologous cell therapy firmly at the top of the list. Chief executive Peter Altman confirmed in a letter published on 18 June that the company intends to file a Shonin submission with Japan's Pharmaceutical and Medical Device Agency (PMDA) in the fourth quarter of 2026, following PMDA support signalled earlier this year.
CardiAMP is designed to treat ischemic heart failure with reduced ejection fraction (HFrEF) using a minimally invasive, autologous approach. The company estimates that around 300,000 patients in Japan live with ischemic heart failure, and said it expects initial approval to focus on a subgroup of approximately 20,000. Altman noted that prior cardiac cell therapies approved in Japan for chronic ischemic heart failure have attracted reimbursement of around $124,000 per procedure, framing Japan as a commercially attractive entry point.
Japan as a regulatory springboard
Beyond the direct commercial opportunity, BioCardia is positioning a Japanese approval as a gateway to broader international registration. Japan holds Primary Member status in the Medical Device Single Audit Programme (MDSAP), alongside the United States, Canada, Australia, and Brazil. A single MDSAP audit satisfying Japan's PMD Act requirements would be accepted by all other participating nations, avoiding the need for repeated factory inspections. Several markets in Southeast Asia, Latin America, and the Middle East also treat Japan as a trusted reference country, which can shorten local evaluation timelines and reduce registration fees for distribution partners. If the Shonin submission lands on schedule, BioCardia believes strategic partners will interpret it as a sign that commercial launch is imminent.
In parallel, the company continues enrolling its confirmatory CardiAMP HF II trial in the United States. The FDA has indicated the study may support a Premarket Approval application. Four sites are currently active with patients in the queue, and BioCardia is working to bring additional centres on board.
Delivery platform and MSC pipeline
Alongside CardiAMP, Altman highlighted two assets BioCardia describes as a "pipeline-in-a-product." Its Helix Transendocardial Delivery Catheter, paired with the Heart3D fusion imaging platform, provides targeted intracardiac delivery that the company says is relevant to more than fifty biotherapeutic programmes currently under development. PMDA has already advised that other developers would be permitted to use Helix under a CardiAMP approval, and BioCardia says it is in early discussions with eight gene and cell therapy programmes targeting cardiac indications worldwide. This delivery-as-a-service model, if it attracts partners, could diversify revenue independent of CardiAMP's own approval timeline.
The company also holds two FDA-approved Investigational New Drug Applications for its allogeneic mesenchymal stem cell (MSC) platform, targeting cardiac and pulmonary indications. Both Japan and the United States have approved MSC therapies for graft-versus-host disease, providing some regulatory precedent for the class.
The cardiac cell and gene therapy space has grown competitive over the past several years, with a number of academic spinouts and well-funded biotechs pursuing regenerative approaches to heart failure. The distinct advantage BioCardia claims is procedural: existing delivery platforms for cardiac biotherapeutics lack the clinical experience accumulated by Helix, which has been used across multiple human studies. Whether that experience translates into a durable licensing moat will depend partly on clinical outcomes data and partly on how quickly the broader field advances.
Altman noted that a recently completed financing round provides sufficient capital to complete the Japan submission, continue HF II enrolment, and pursue partnership discussions. The company said it is watching for revised SEC regulations expected later in 2026 that could ease capital access for smaller reporting companies.